ACM
ACOR

Asymmetry Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Asymmetry Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,213
Closed -$6.22M – 20
2015
Q4 		$6.22M Buy
+1,213
New +$5.3M 9.41% 4

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Asymmetry Capital Management's ACOR Position: Q1 2016 in Review

Asymmetry Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2016, closing a stake of 1,213 shares — an estimated $6.22M sold.

Asymmetry Capital Management first reported a position in ACOR in Q4 2015 and held it in 1 quarter. The position peaked at $6.22M in Q4 2015. 194 funds tracked by Wall St. Rank hold ACOR as of Q1 2016.

  • Asymmetry Capital Management reported no remaining Acorda Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Asymmetry Capital Management sold 1,213 Acorda Therapeutics shares in Q1 2016, an estimated $6.22M.
  • Asymmetry Capital Management first reported a position in Acorda Therapeutics in Q4 2015 and held it in 1 quarter.
  • Asymmetry Capital Management's Acorda Therapeutics position peaked at $6.22M in Q4 2015.
  • 194 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2016.

Based on Asymmetry Capital Management's 13F filing for Q1 2016, filed 21 Apr 2016.